Table 2.

Mortality and proportion of patients alive and discharged without supplemental oxygen on day 29

Characteristics	Statistics	Meplazumab + SoC			Placebo + SoC (N = 41)
Characteristics	Statistics	0.12 mg/kg (N = 41)	0.2 mg/kg (N = 41)	0.3 mg/kg (N = 44)	Placebo + SoC (N = 41)
Patients who died by day 29	n (%)	1 (2.4)	6 (14.6)	4 (9.1)	6 (14.6)
	Difference in proportions^a	−12.2	0	−5.5
CMH^†	p-value	0.0150	0.9923	0.7291
Patients alive and discharged without supplemental oxygen by day 29	n (%)	34 (82.9)	27 (65.9)	31 (70.5)	29 (70.7)
	Difference in proportions^a	12.2	−4.8	−0.2
CMH^†	p-value	0.0337	0.4943	0.8286

Note: Day of death was derived as (Date of death—Date of randomization + 1)

Note: Percentages are based on the number of patients in the analysis set by treatment group

Note: Patients with no data on day 29 are treated as a non-responder

^aThe difference in proportions is calculated as: the proportion of dose group—the proportion of control group

^†p-value from a CMH test adjusted for age group (age < 65 years versus ≥65 years) and baseline severity grade

Abbreviations: CMH Cochran-Mantel-Haenszel, N number of patients in analysis set, n number of patients, SoC Standard of Care